Industry News

KemPharm and its Officers and Directors have violated the federal securities laws. KemPharm is a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. KemPharm was founded in 2006 and is headquartered in Coralville, Iowa."/>
Zeldes Haeggquist & Eck, LLP Announces Investigation of KemPharm, Inc.
Briefcase [Albuquerque Journal, N.M.]
Teva Pharmaceutical Industries Ltd. today announced that it has completed its acquisition of Anda, Inc., a leading distributor of generic pharmaceuticals in the U.S., from Allergan plc.. “We are pleased that Anda, Inc., one of the leading distributors of generic medicines in the U.S., is now part of Teva."/>
Teva Completes Acquisition of Anda, Inc.
Pulmatrix, Inc., a pharmaceutical company developing innovative inhaled drugs, announced today that the company has appointed Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Acceleron Pharma, Inc., a clinical stage biopharmaceutical company as a new member to its Board of Directors. Sherman has extensive experience in drug development. Before joining Acceleron in 2006, he was head of clinical research and..."/>
Dr. Matthew L. Sherman Joins Pulmatrix's Board of Directors
Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Dr. Barbara Troupin, M.D. as Chief Medical Officer and Vice President, Clinical Development. Troupin will lead overall clinical and medical affairs strategies for Aquinox’ s ongoing programs as well as future..."/>
Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer
IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger of IMS Health, a leading global information and technology services company, and Quintiles, the world’ s largest provider of product development and integrated healthcare services, creates a leading information and tech-enabled..."/>
QuintilesIMS: Merger Creates a Leading Global Integrated Information and Technology-Enabled Healthcare Service Provider
IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger of IMS Health, a leading global information and technology services company, and Quintiles, the world’ s largest provider of product development and integrated healthcare services, creates a leading information and tech-enabled..."/>
QuintilesIMS: Merger Creates a Leading Global Integrated Information and Technology-Enabled Healthcare Service Provider
GeoVax Labs, Inc., a biotechnology company specializing in developing human vaccines, announced today that its Senior Vice President of Research and Development, Dr. Farshad Guirakhoo, will present at three upcoming scientific conferences. At the 2016 International Society for Vaccines Annual Congress, being held in Boston, MA on October 2-4, Dr."/>
GeoVax to Present at Upcoming Scientific Conferences on Its Hemorrhagic Fever and Zika Vaccine Programs
Press Ganey clients access to Cleveland Clinic’ s foundational communication model. BOSTON---- Press Ganey Holdings, Inc. is collaborating with Cleveland Clinic to distribute and implement its“ Communicate with H.E.A.R.T.” program to hospitals looking to improve their patient experience. The program, created and launched at Cleveland Clinic in 2010, has played a significant role in the improvement of organizational culture and reinforcing..."/>
Press Ganey to Offer Cleveland Clinic H.E.A.R.T.® Program
Collegium Pharmaceutical, Inc. announced today the submission of a New Drug Submission to Health Canada seeking marketing approval of Xtampza ® ER, an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.. “Submitting the NDS in Canada for Xtampza ER is an important milestone for Collegium and a..."/>
Collegium Submits New Drug Submission to Health Canada for Xtampza® ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
Diversicare Healthcare Services, Inc., a premier provider of long-term care services, effective October 1, 2016 entered into an agreement with Golden Living to assume the operations of ten facilities in Mississippi previously operated by Golden Living. Eight of these facilities are leased directly from Golden Living and the Company assumed the individual leases of two additional facilities that are privately owned. This transaction increases..."/>
Diversicare Acquires 10 Facilities in Mississippi
Biotechs with Key Corporate Developments
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today commemorates the 10- year anniversary of the Nobel Prize in Physiology or Medicine awarded to Andrew Fire, Ph.D. and Craig Mello, Ph.D. for their discovery of RNA interference. Their research enabled an elevated understanding of gene function and advancement of one of the most promising new areas..."/>
Alnylam Commemorates 10th Anniversary of the Nobel Prize in Physiology or Medicine Awarded for the Discovery of RNAi
Laboratory Corporation of America ® Holdings announced today that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee and the conversion agent. In order to exercise the option to convert..."/>
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
Align Technology, Inc. announced today that the Company will report third quarter 2016 financial results on Monday, November 7, 2016 after the close of market. Q3'16 is Align's first quarter in which it will report its financial results using its new ERP system implemented in July 2016. This extended report date allows time for the Company to prepare for the announcement using the new system. Financial results will be released at 4:00 p.m. ET and will be..."/>
Align Technology to Announce Third Quarter 2016 Results on November 7, 2016
Quorum Health Corporation announced today that subsidiaries of the Company have signed a definitive agreement to sell 56- bed Barrow Regional Medical Center in Winder, Georgia, and its associated assets, to Northeast Georgia Health System, Inc. The divestiture is expected to close December 31, 2016, subject to customary regulatory approvals and closing conditions. "We have executed our first definitive agreement related to our previously disclosed..."/>
Quorum Health Corporation Announces Definitive Agreement to Divest Hospital in Winder, Georgia
Boston Scientific Corporation will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2016 on Wednesday, October 26, 2016 at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. A live webcast of the conference call will be available on the Investor..."/>
Boston Scientific to Webcast Conference Call Discussing Third Quarter 2016 Financial Results on October 26
VIVUS, Inc. and Metuchen Pharmaceuticals LLC today announced an agreement providing Metuchen a fully-paid, perpetual license for exclusive rights to commercialize STENDRA ® in the U.S., Canada, South America and India. The parties simultaneously signed a commercial supply agreement pursuant to which VIVUS will be responsible for the manufacture and supply of STENDRA to Metuchen for a mutually agreed term. For a period of 180 days,..."/>
VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial Rights to STENDRA
Jazz Pharmaceuticals plc today announced the initiation of a rolling submission of a New Drug Application to the United States Food and Drug Administration on September 30, 2016, seeking marketing approval of Vyxeos™, an investigational agent for the treatment of acute myeloid leukemia. The company expects to complete the submission of the NDA by early 2017, and will request a priority review. "Our initiation of the rolling NDA submission for..."/>
Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017
Hemostemix Inc., a clinical-stage autologous cell-therapy company, announces that two new patents have been granted in 2016 in the United States and Canada. Patent and Trademark Office granted patent US 9,404,084 titled "Regulating Stem Cells". Itis the fourth Hemostemix patent issued in the United States."/>
Hemostemix Granted Two Additional Patents in the US and in Canada
Thermo Fisher Scientific, the world leader in serving science, today announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan."/>
Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan
CareDx, Inc., a molecular diagnostics company, today called for a reversal of a decision by the Centers for Medicare& Medicaid Services to drastically reduce reimbursement for its diagnostic test AlloMap– the only FDA-cleared blood test to monitor heart transplant patients for rejection, and the only alternative to more costly and invasive biopsies. "This decision is unwise, unfair, and misaligned with President Obama's Precision Medicine..."/>
CMS Proposal Threatens Availability Of Standard Of Care Blood Test To Heart Transplant Patients
Arena Pharmaceuticals, Inc. today announced the availability of BELVIQ XR ® CIV extended-release 20 mg tablets, a new once-daily dosing option that may help some patients achieve and maintain weight loss. "With more than 78 million adults who are obese in this country and obesity rates on the rise, there is an increased need for additional therapeutic options to help patients better manage their weight," said..."/>
Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology690 Articles
Consumer Discretionary665 Articles
Financials605 Articles
Industrials446 Articles
Health Care437 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at